Open AccessThis article is
- freely available
Rafts, Nanoparticles and Neural Disease
Ross University School of Medicine, Miami Beach Community Health Center, 11645 Biscayne Boulevard, North Miami, FL 33181, USA
Department of Anthropology, University of Central Florida, Orlando, FL 32816, USA
* Author to whom correspondence should be addressed.
Received: 12 June 2012; in revised form: 19 July 2012 / Accepted: 20 July 2012 / Published: 6 August 2012
Abstract: This review examines the role of membrane rafts in neural disease as a rationale for drug targeting utilizing lipid-based nanoparticles. The article begins with an overview of methodological issues involving the existence, sizes, and lifetimes of rafts, and then examines raft function in the etiologies of three major neural diseases—epilepsy, Parkinson’s disease, and Alzheimer’s disease—selected as promising candidates for raft-based therapeutics. Raft-targeting drug delivery systems involving liposomes and solid lipid nanoparticles are then examined in detail.
Keywords: rafts; nanoparticles; nanomedicine; neural disease; epilepsy; Parkinson’s disease, Alzheimer’s disease; liposomes; solid lipid nanoparticles
Citations to this Article
Cite This Article
MDPI and ACS Style
Gulati, V.; Wallace, R. Rafts, Nanoparticles and Neural Disease. Nanomaterials 2012, 2, 217-250.
Gulati V, Wallace R. Rafts, Nanoparticles and Neural Disease. Nanomaterials. 2012; 2(3):217-250.
Gulati, Vishal; Wallace, Ron. 2012. "Rafts, Nanoparticles and Neural Disease." Nanomaterials 2, no. 3: 217-250.